US Veterans Affairs researchers studied 215,970 adults with diabetes who started a GLP-1 drug [1]. Research on GLP-1 versus SGLT2 inhibitors shows how the choice of comparator can change the question. This study used both several active treatments and a usual-care comparison group.
What the study found
Compared with usual care, GLP-1 use was associated with lower risks of several cardiovascular, cognitive and substance-use diagnoses [1]. It was also associated with higher risks of several digestive disorders, low blood pressure, fainting and kidney stones. The comparison describes population averages and does not establish that the drugs caused each association.
The atlas also flagged drug-induced pancreatitis compared with usual care. More focused research on GLP-1 treatment and pancreatitis examines a specific concern. A later VA analysis distinguished suspected drug-induced pancreatitis from other causes [2]. Compared with sulfonylureas, GLP-1 users had more suspected drug-induced cases. Across all causes, the one-year difference was −3.64 cases per 100,000 people (95% CI −30.76 to 23.48).
Who the findings apply to
The studies of erectile function during GLP-1 treatment use measures specific to that outcome. Read them separately from the broad associations in the VA records.
The review of GLP-1 drugs for idiopathic intracranial hypertension addresses a specific neurological condition. It examines targeted studies with different methods from this analysis.
The cohorts were primarily older men with diabetes who received care in the VA system. Risks may differ for people taking a GLP-1 for weight management without diabetes. The findings can guide further research. They do not establish effectiveness for conditions such as dementia.